ABSTRACT
Reduction in the level of blood pressure (BP) from 140/90 to 130/80 mm Hg for defining hypertension is one of the major practice changing modifications of the 2017 American College of Cardiology/American Heart Association guidelines which are bound to have a huge societal impact. The number of hypertension patients will increase 1.5 times after this definition change. Although the BP levels for defining hypertension have changed, the levels at which pharmacological therapy should be started have remained the same, i.e., ≥140/90 mm Hg (Stage 2 hypertension according to newer guidelines) except in special situations (clinical atherosclerotic cardiovascular disease or estimated 10-year cardiovascular disease risk of ≥10%). All in all, definitely these guidelines are more comprehensive, give a much more clarity to the treating physician, and are aimed at better long-term prevention of target-organ damage. But at the same time, they leave us in the same dilemma which arises after every major guideline change: how to deal with patients who are being treated as per the old guidelines?

DEFINITION CHANGE: IS IT JUST NUMBERS?
Although the BP levels for defining hypertension have changed, the levels at which pharmacological therapy should be started have remained the same, i.e., ≥140/90 mm Hg (Stage 2 hypertension according to newer guidelines) except in special situations (clinical atherosclerotic cardiovascular disease or estimated 10-year cardiovascular disease risk of ≥10%).

Lowering the BP levels for defining hypertension means that a large group of population which was earlier considered as normotensive will be now considered as hypertensive. For example, according to Joint National Committee (JNC 7) definition, 32% of the adult population of the United States was hypertensive which has increased to 46% after the definition change.1 A similar increase in the prevalence of hypertension by 1.5 times may be seen in Indian scenario also. At the same time, the number of hypertensives on pharmacological therapy will remain more or less the same in general population without high-risk features.

So, can we say that the newer guidelines will just change the current statistics? Probably not:
• By labeling patients with BP more than 130/80 mm Hg as hypertensives, lifestyle modifications (nonpharmacological interventions) can be initiated early and likely to be more acceptable
• This gives a lot of time for patient education and bringing disease awareness
• Closer follow-up of hypertensive patients who are not yet requiring pharmacotherapy (stage 1 hypertension) ensures earlier initiation of pharmacotherapy
• This might go a long way in preventing target organ damage.

Is it really as good as it sounds? Again, probably not:
An almost 50% increase in prevalence is not just a number. As far as psychosocial impact of the disease is concerned, numbers do matter!!!

SO WHY WERE THE TARGETS LOWERED?
A large meta-analysis has shown that with every 20 mm Hg systolic and 10 mm Hg diastolic rise in BP (starting from 115/75 to 180/110 mm Hg), the cardiovascular mortality...
CHANGING TREATMENT TARGETS: A CLINICAL CHALLENGE, A SOCIOECONOMIC BURDEN OR NEED OF THE HOUR?

Another important change that these new guidelines have brought about is the revision of treatment target to <130/80 mm Hg.

If we look at the data from the Prospective Urban and Rural Epidemiological (PURE) study, only 40% of the hypertensives receiving treatment had BP <140/90 mm Hg. Numbers are still less (12.7%) if we include those unaware of the disease and those not receiving treatment.7 By taking the BP target further down, the number of people with adequate BP control will decrease further.

Achieving new targets will be a clinical challenge and the reasons are manifold:

- A lot of patients in the BP range of 130/80 to 140/90 mm Hg who were being assured that their hypertension is being adequately controlled will now have to be conveyed that they need to maintain lower targets.
- Even for elderly patients, the systolic BP targets have been revised to <130 mm Hg except in situations where clinical judgment precludes intensive control.
- With the ever-increasing prevalence of noncommunicable diseases, balancing the drug–drug interactions and drug side effects with clinical benefit is not an easy task.
- Further lowering the targets will not only add to the pill burden but also increase in cost therapy—an addition to the economic burden, especially in the low-income households.

Another important change is the recommendation to start with two antihypertensives in stage 2 hypertension (BP ≥140/90 mm Hg). When to start with two drugs has always been a confusion, as there was never a clear-cut recommendation. This will come as a relief, especially to general physicians.

Newer guidelines have also clarified the concept of masked and white-coat hypertension further, with clear-cut suggestions on how to deal with these situations. The importance of home BP monitoring and ambulatory BP monitoring could not have been stressed in a better way. Even the nonpharmacological therapy has been given its due importance and has been very distinctly and precisely mentioned.

PSYCHOSOCIAL AND ECONOMIC IMPACT

After pondering upon the fact that strict control is required for clinical benefit, now it is necessary to talk about the problems associated. Hypertension is a chronic disease and once labeled, it is for a lifetime. Studies have shown that patients being labeled as hypertensive may adopt a sick role and in turn affect their quality of life.3 The association of psychological distress with hypertension may be directly due to BP, side effects of medications, or the consequence of being labeled as hypertensive. Like other chronic illnesses, hypertension also has immense emotional impact leading to anxiety and depression.6,10

India is a developing country and comes under low-income countries. Expenditure on health is of utmost importance and should be properly looked after. Strict control of BP results in multidrug prescriptions which in turn leads to higher economic burden and poorer compliance. Not only this, multidrug therapy leads to higher incidence of side effects. In 2004, the annual income loss due to noncommunicable diseases was 251 billion rupees and that due to hypertension alone was 43 billion rupees.11 The benefit of treating high-risk group is acceptable but for patients in low-risk category, aggressive treatment is only going to add to the economic burden (as emphasized in these guidelines).

The impact of these guidelines is manifold. The emphasis should be on high-risk population and strict control of BP has the maximum benefit in this subgroup.

All in all, definitely these guidelines are more comprehensive, give much more clarity to the treating physician, and are aimed at better long-term prevention of target-organ damage. But at the same time, they leave us in the same dilemma which arises after every major guideline change—how to deal with patients who are being treated as per the old guidelines.
In the present scenario, where the noncommunicable diseases are toward a rising trend, the newer guidelines are very much welcome, but then all good things come with a pinch of salt.

REFERENCES